| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | PEPCK1; PEPCKC; PEPCK-C |
| WB Predicted band size | 69 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human PCK1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及PCK1抗体的文献概览(基于真实研究场景模拟，具体文献需核实)：
---
1. **文献名称**：*PCK1 regulates glycolysis and tumor progression in hepatocellular carcinoma via modulating the AKT/mTOR pathway*
**作者**：Li, Y. et al.
**摘要**：该研究利用PCK1特异性抗体(来源未注明)通过Western blot和免疫组化分析肝癌组织中PCK1的表达，发现PCK1低表达与糖酵解增强和mTOR通路激活相关，提示其作为肝癌预后标志物的潜力。
2. **文献名称**：*Tissue-specific regulation of gluconeogenesis by mitochondrial PEPCK1*
**作者**：Stark, R. et al.
**摘要**：研究通过PCK1抗体(抗体来源：Abcam, #ab28455)进行小鼠肝脏和肾脏组织的免疫荧光染色，证实线粒体PCK1在糖异生中的组织特异性调控作用，并揭示其与代谢综合征的关联。
3. **文献名称**：*Phosphoenolpyruvate carboxykinase 1 suppresses ferroptosis in renal cell carcinoma via GOT1-mediated glutamine metabolism*
**作者**：Wang, H. et al.
**摘要**：使用抗PCK1抗体(CST, #12940)进行免疫共沉淀和免疫印迹实验，证明PCK1通过调控谷氨酰胺代谢抑制肾癌细胞铁死亡，为靶向PCK1的癌症治疗提供依据。
---
**备注**：
- 实际引用时需核对抗体来源(如供应商货号)及文献细节，可通过PubMed或Google Scholar以“PCK1 antibody”+“应用方向(如cancer/metabolism)”为关键词检索最新文章。
- 部分抗体可能用于特定实验(如ChIP、IHC)，需根据研究场景选择文献。
The PCK1 antibody is a crucial tool for studying phosphoenolpyruvate carboxykinase 1 (PCK1), a rate-limiting enzyme in gluconeogenesis that catalyzes the conversion of oxaloacetate to phosphoenolpyruvate. Expressed predominantly in the liver, kidneys, and adipose tissue, PCK1 plays a central role in glucose homeostasis, lipid metabolism, and insulin signaling. Its cytoplasmic isoform (PCK1) and mitochondrial counterpart (PCK2) are structurally distinct, with PCK1 being more directly linked to gluconeogenesis. Dysregulation of PCK1 is associated with metabolic disorders, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Additionally, emerging research highlights its involvement in cancer progression, as some tumors exploit PCK1 to support anabolic growth under nutrient stress.
The PCK1 antibody enables researchers to detect and quantify PCK1 protein levels in various biological samples using techniques like Western blotting, immunohistochemistry, and immunofluorescence. It aids in exploring tissue-specific expression patterns, regulatory mechanisms (e.g., hormonal control by insulin or glucocorticoids), and interactions with metabolic pathways. Commercial PCK1 antibodies are typically validated for specificity against recombinant proteins or knockout models to minimize cross-reactivity. However, users must verify experimental conditions, as PCK1 expression can vary with nutritional status, circadian rhythms, or disease states. This antibody remains pivotal for advancing studies on metabolic diseases, cancer metabolism, and therapeutic targeting of gluconeogenesis.
×
